These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 22268382)

  • 1. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
    Taylor TE; Furnari FB; Cavenee WK
    Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
    Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB
    Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
    Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
    Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
    Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
    Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.
    Lo HW
    Curr Mol Pharmacol; 2010 Jan; 3(1):37-52. PubMed ID: 20030624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
    Kalman B; Szep E; Garzuly F; Post DE
    Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
    Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
    Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
    Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
    J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
    Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
    Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.
    Roth P; Weller M
    Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii14-9. PubMed ID: 25342600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges.
    Reardon DA; Wen PY; Mellinghoff IK
    Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii7-13. PubMed ID: 25342602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
    Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
    Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term responses with cetuximab therapy in glioblastoma multiforme.
    Belda-Iniesta C; Carpeño Jde C; Saenz EC; Gutiérrez M; Perona R; Barón MG
    Cancer Biol Ther; 2006 Aug; 5(8):912-4. PubMed ID: 16929166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.
    McKinney A; Lindberg OR; Engler JR; Chen KY; Kumar A; Gong H; Lu KV; Simonds EF; Cloughesy TF; Liau LM; Prados M; Bollen AW; Berger MS; Shieh JTC; James CD; Nicolaides TP; Yong WH; Lai A; Hegi ME; Weiss WA; Phillips JJ
    Mol Cancer Ther; 2019 Sep; 18(9):1565-1576. PubMed ID: 31270152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
    Cemeus C; Zhao TT; Barrett GM; Lorimer IA; Dimitroulakos J
    J Neurooncol; 2008 Oct; 90(1):9-17. PubMed ID: 18566746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma.
    Kwatra MM
    Curr Cancer Drug Targets; 2017; 17(3):290-296. PubMed ID: 28029074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
    Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
    Eller JL; Longo SL; Hicklin DJ; Canute GW
    Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.